Targeting mTOR for Cancer Treatment
Belén Rubio‐Viqueira, Manuel M. Hidalgo · Advances in experimental medicine and biology · 2006
Cited by 69 works. doi:10.1007/978-1-4020-5133-3_24
Authors
References
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs
- Regulation of translation initiation by FRAP/mTOR
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice
- The mRNA 5′ cap-binding protein eIF4E and control of cell growth
- p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
- Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability
- Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.